Investment Rating - Investment Rating: Buy (Maintain) [3] Core Views - The company is expected to accelerate store openings in the second half of 2025, with a strong willingness from franchisees to cooperate, particularly in underpenetrated markets [10] - The company achieved a core operating profit margin of 7.7% in Q4 2025, a year-on-year increase of 1.2 percentage points, driven by scale effects and operational efficiency improvements [9] - Revenue for Q4 2025 is projected at 2.61 billion yuan, a year-on-year increase of 19.9%, while the core operating profit is expected to reach 200 million yuan, up 41.8% year-on-year [13] Revenue Summary - The company exceeded its store opening targets, adding 805 new stores in Q4 2025, significantly accelerating compared to previous quarters [14] - The average monthly revenue per store in Q4 2025 is estimated at 64,000 yuan, reflecting an 8.7% year-on-year growth [14] - Total revenue forecasts for 2025-2027 are 7.646 billion, 9.031 billion, and 10.619 billion yuan, representing year-on-year growth rates of 18.2%, 18.1%, and 17.6% respectively [11] Profitability Summary - The company is expected to achieve net profits of 429 million, 581 million, and 749 million yuan for 2025-2027, with year-on-year growth rates of 86.2%, 35.3%, and 29.0% respectively [11] - The projected price-to-earnings (P/E) ratios for the next three years are 24, 18, and 14 times [11] Financial Indicators - Key financial indicators for 2025 include a return on equity (ROE) of 12.72% and earnings per share (EPS) of 0.16 yuan [15] - The company’s gross margin is expected to remain stable around 21.79% to 21.93% over the forecast period [16]

Investment Rating - The report assigns an "Accumulate" rating for the company, indicating a potential stock price increase of 5% to 15% over the next six months [5]. Core Insights - The company reported a revenue of 2.312 billion yuan for the first half of FY2026, representing a year-on-year growth of 5.7%, and achieved a net profit of 239 million yuan, marking a turnaround from losses [1]. - The growth in Gross Merchandise Volume (GMV) is driven by self-operated products, which accounted for 52.8% of total GMV, up from 43.8% in FY2025. The total GMV for FY2026H1 was 4.1 billion yuan, a decrease of 15% [2]. - The company has expanded its product categories to 801 SKUs, including new categories like seafood and health supplements, enhancing consumer choices and driving sales [2]. - Profitability has significantly improved, with gross margin increasing from 33.6% to 36.4%, attributed to supply chain expansion and category growth. The net profit margin for FY2026H1 was 10.34% [2]. Membership Growth and Brand Recognition - The company has seen a continuous increase in paid membership, reaching 240,000, with its app contributing 18.5% to total GMV. The self-operated GMV through the app remained stable at 28.6% [3]. - The company is expanding its sales channels across multiple platforms, with plans to open its first offline experience store in Beijing in 2026, which is expected to enhance brand influence [3]. Financial Projections - The company forecasts adjusted net profits of 497 million yuan, 540 million yuan, and 590 million yuan for FY2026, FY2027, and FY2028, respectively [3]. - Revenue projections for the upcoming years are as follows: 4.828 billion yuan in FY2026, 5.254 billion yuan in FY2027, and 5.633 billion yuan in FY2028, reflecting growth rates of 9.92%, 8.84%, and 7.21% respectively [4].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage in the market [5][9][47]. Core Insights - The company, known as a leader in the spicy snack sector, has successfully capitalized on the industrialization of snacks and has redefined standards and consumer perceptions in the spicy strip market. The company benefits from a strong brand and channel power, ensuring its competitive edge [5][6][11]. - The domestic spicy snack market is growing rapidly, with significant potential in the konjac market. The company has established a strong presence in both spicy strips and konjac snacks, leveraging its first-mover advantage and comprehensive advantages in product categories, branding, and distribution channels [6][25][39]. - The company is expected to maintain high profitability driven by its konjac product line, with projected net profits for 2025-2027 of 1.384 billion, 1.696 billion, and 2.012 billion RMB, respectively, reflecting growth rates of 29.53%, 22.52%, and 18.65% [7][46]. Summary by Sections Market Performance - As of January 30, 2026, the closing price of the company's stock is 12.29 HKD, with a market capitalization of approximately 29.88 billion HKD [3]. Financial Projections - The company is projected to achieve revenues of 73.73 billion, 86.51 billion, and 99.69 billion RMB for the years 2025-2027, with year-on-year growth rates of 18%, 17%, and 15% respectively [9][46]. - The konjac product line is expected to see revenue growth rates of 38%, 26%, and 21% during the same period, indicating strong market demand [10][46]. Competitive Landscape - The spicy snack market in China is characterized by a high concentration of brands, with the company holding a significant market share of 28% in the spicy strip segment, far ahead of competitors [25][35]. - The company has a robust distribution network, covering approximately 690,000 retail outlets across China, and is actively exploring international markets, including North America and Southeast Asia [40][39]. Growth Drivers - The company is focusing on product innovation and expanding its product offerings, including new flavors and overseas market penetration, which are expected to drive future growth [40][11]. - The report highlights the company's strategic initiatives to enhance its brand positioning and operational efficiency, which are anticipated to sustain its competitive advantage in the market [39][40].

Investment Rating - The report assigns a "Buy" rating for Yum China (09987.HK) [6] Core Insights - The Western fast food industry is expected to expand significantly, with a market size projected to exceed 300 billion yuan by 2025, reflecting a year-on-year growth of 10.3% [1] - Yum China holds a leading market share of 27.5% in the fast food sector, with a high concentration of market power among top brands [1][27] - The company has a strong local innovation capability and a mature supply chain, supporting healthy profitability across its stores [2][29] - The expansion into lower-tier markets is accelerating, with new store formats like KFC Mini and Pizza Hut WOW being introduced [3][29] Summary by Sections 1. Industry Expansion and Market Concentration - The Western fast food market is projected to grow at a compound annual growth rate (CAGR) of 8% from 2020 to 2025, with fast food leading the growth among various segments [21] - The market concentration is increasing, with the top five brands expected to account for 44% of the market share by 2024 [27] 2. Brand Stability and Shareholder Returns - As of Q3 2025, Yum China operates 17,514 stores, with a CAGR of 9% from 2014 to 2024 [2] - The company reported a free cash flow of $1.517 billion in 2024, achieving a shareholder return rate of 166.49% [2] - The membership base reached 575 million, contributing to 57% of sales, indicating strong customer loyalty [2] 3. Accelerated Expansion in Lower-Tier Markets - The introduction of smaller store formats is aimed at penetrating lower-tier cities, with franchise models becoming a core growth engine [3] - The overall restaurant profit margin was reported at 17.3% as of Q3 2025, with continuous improvement in cost control [3] 4. Investment Recommendations - The report anticipates revenues of $11.7 billion, $12.4 billion, and $13.1 billion for 2025, 2026, and 2027 respectively, with net profits of $925 million, $1 billion, and $1.08 billion [4][17] - The current price corresponds to a price-to-earnings (P/E) ratio of 19, 18, and 16 for the years 2025, 2026, and 2027 respectively, reflecting a strong growth outlook [17]

2026 年 2 月 2 日 公司研究 因内码调整进度偏慢拖累，预计 25H2 业绩承压 ——澳优（1717.HK）2025 年业绩前瞻 资料来源：Wind，光大证券研究所预测，股价时间为 2026-01-30 （注：汇率为 1 港币=0.8926 元人民币，23-27 年股本 数分别为 17.80/17.80/17.78/17.78/17.78 亿股） 要点 2025 年业绩前瞻：1）我们预计公司 25 年收入同比增长 1.1%，收入增速较 25H1 放缓主要受国内奶粉业务拖累。2）我们预计公司 25 年归母净利润同比基本持 平；25H2 利润同比下滑主要系内码调整进度低于预期，以及行业竞争加剧，导 致高毛利率的国内奶粉业务收入占比下降。 内部调整滞后、外部行业环境恶化等因素影响，25 年业绩预计不及预期。 1）内码切换进度滞后：25 年 4 月公司启动内码切换工作并同步涨价，消费者提 前囤货，使得内码切换完成时间从三季度延迟至四季度，打乱了下半年核心业务 的增长节奏。2）行业竞争加剧：25 年行业内多家企业推出补贴或降价策略，而 公司此时处于涨价阶段，在价格竞争中处于被动地位。3）行业收入增速下滑： 25 ...

2026 年 02 月 02 日 公司研究 评级：买入(首次覆盖) 研究所： 证券分析师： 曹泽运 S0350525110001 证券分析师： 万鹏辉 S0350524050003 caozy@ghzq.com.cn wanph@ghzq.com.cn [Table_Title] 与齐鲁制药达成合作，持续验证 AI 制药能力 ——英矽智能（03696）点评报告 最近一年走势 事件: 2026 年 1 月 27 日，英矽智能发布公告：公司与齐鲁制药签署战略合作 协议，双方将围绕心血管与代谢类疾病领域，利用英矽智能的 Pharma.AI 平台进行小分子抑制剂的研发。协议总金额超过 9.31 亿港元，包含开发 和销售里程碑付款，以及单位数的后续净销售额分成。 投资要点: | 相对恒生指数表现 | | 2026/01/30 | | | --- | --- | --- | --- | | 表现 | 1M | 3M 12M | | | 英矽智能 | 109.8% | - | - | | 恒生指数 | 5.9% | - | - | | 市场数据 | | 2026/01/30 | | | 当前价格（元） | | 62.90 ...

证券研究报告 | 2026年02月01日 锅圈（02517.HK） 利润率优化明显，门店扩张驱动高增长 优于大市 |  | 公司研究·海外公司快评 |  | 社会服务·酒店餐饮 | 投资评级：优于大市（维持）  | | --- | --- | --- | --- | --- | | 证券分析师： | 张向伟 | | zhangxiangwei@guosen.com.cn | 执证编码：S0980523090001 | | 证券分析师： | 曾光 | 0755-82150809 | zengguang@guosen.com.cn | 执证编码：S0980511040003 | | 证券分析师： | 张鲁 | 010-88005377 | zhanglu5@guosen.com.cn | 执证编码：S0980521120002 | | 联系人： | 王新雨 | 021-60875135 | wangxinyu8@guosen.com.cn | | 事项： 公司公告：锅圈发布盈利预告，2025 年全年预计实现收入约 77.50-78.50 亿元，同比增长约 19.8%-21.3%； 预计录得净利润约 4.43 ...

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Insights - The strategic partnership with Sony aims to establish a joint venture for integrated operations in the home entertainment sector, which includes television and audio products [9] - The collaboration is expected to leverage both companies' strengths, enhancing technology, scale, and global presence [9] - Revenue projections for 2025-2027 are estimated at HKD 116.4 billion, HKD 132.3 billion, and HKD 145.8 billion, respectively, with corresponding net profits of HKD 26 billion, HKD 31 billion, and HKD 36 billion [9][10] - The report anticipates a significant increase in earnings per share (EPS) from HKD 0.30 in 2023 to HKD 1.43 by 2027 [4][14] Financial Projections - Revenue (in million HKD): - 2023A: 78,986 - 2024A: 99,322 - 2025E: 116,386 - 2026E: 132,328 - 2027E: 145,814 - Growth Rates (%): - 2023A: 10.7% - 2024A: 25.7% - 2025E: 17.2% - 2026E: 13.7% - 2027E: 10.2% [4] - EBITDA (in million HKD): - 2023A: 3,229 - 2024A: 4,457 - 2025E: 5,421 - 2026E: 6,578 - 2027E: 7,205 [4] Profitability Metrics - Return on Equity (ROE) is projected to increase from 4.5% in 2023 to 16.2% in 2027 [4] - The report estimates a PE ratio of 13x for 2026, leading to a target price of HKD 16.25 per share [9][14] Business Segments - Display Business Revenue (in million HKD): - 2024A: 69,440 (YoY: 23%) - 2025E: 77,884 (YoY: 12%) - 2026E: 86,430 (YoY: 11%) - 2027E: 94,691 (YoY: 10%) [11] - Innovative Business Revenue (in million HKD): - 2024A: 27,009 (YoY: 45%) - 2025E: 35,386 (YoY: 31%) - 2026E: 42,376 (YoY: 20%) - 2027E: 47,192 (YoY: 11%) [11] - Internet Business Revenue (in million HKD): - 2024A: 2,627 (YoY: -5%) - 2025E: 3,038 (YoY: 16%) - 2026E: 3,440 (YoY: 13%) - 2027E: 3,845 (YoY: 12%) [11]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.25 [1][4]. Core Insights - The company has announced a significant overseas deal for its long-acting peptide drug metabolism AI discovery platform, involving an upfront payment of USD 1.2 billion, potential R&D milestone payments of up to USD 3.5 billion, and sales milestone payments of up to USD 13.8 billion, along with a double-digit percentage royalty on net sales to AstraZeneca [1][2]. - This transaction is noted as the largest deal in the domestic pharmaceutical sector for the year, comparable to a previous major deal between 3SBio and Pfizer [1]. - The company is expected to benefit from the upfront payment, leading to a projected rapid year-on-year growth in net profit for 2026 [1]. - The long-acting metabolism platform is considered rare globally, with only Camurus having a similar platform, which enhances the company's competitive position in the overseas weight loss market [2]. Summary by Sections Transaction Details - The deal with AstraZeneca includes an upfront payment of USD 1.2 billion, potential R&D milestones of up to USD 3.5 billion, and sales milestones of up to USD 13.8 billion, along with a royalty on net sales [2]. - The platform includes core assets such as GIPR/GLP-1R and three preclinical weight loss pipelines, with plans for collaboration on four additional projects [2]. Platform Mechanism - The company possesses a leading liposome platform, and the fluid crystal technology allows for long-term release of active ingredients, enabling monthly or longer dosing [2]. Pipeline Potential - The company has a robust pipeline including EGFR ADC, which is expected to enter Phase III clinical trials both domestically and internationally, and other oncology and autoimmune therapies [3]. - The ADC pipeline targets HER3, B7H3, DLL3, and aims to address gaps in lung squamous carcinoma treatment [3]. Profit Forecast and Valuation - The projected net profits for the company from 2025 to 2027 are estimated at RMB 4.45 billion, RMB 8.46 billion, and RMB 5.60 billion respectively, with corresponding EPS of RMB 0.39, RMB 0.73, and RMB 0.49 [4][9]. - The company is assigned a PE ratio of 24 times for 2026, with a target price adjustment reflecting market conditions [4][11].

Investment Rating - The investment rating for the company is "Buy" [8] Core Insights - The company has experienced a turnaround in operations, with significant growth in product and channel expansion since the appointment of the new CEO in December 2025 [1][3] - For FY2026H1, the company reported revenue of 2.3 billion yuan, a year-on-year increase of 5.7%, and a 17% increase when adjusted for previous consolidation effects [1][18] - The gross merchandise volume (GMV) for FY2026H1 reached 4.1 billion yuan, with a 16.4% year-on-year increase after adjusting for previous consolidation effects [1][18] - The company's self-operated products generated a GMV of 2.16 billion yuan, reflecting a 22% year-on-year growth and accounting for 52.8% of total sales, marking it as the core growth driver [1][18] Summary by Sections FY2026H1 Financial Report: Self-Operation as Core Driver, Significant Improvement in Profitability - The gross margin for FY2026H1 was 36.4%, an increase of 2.8 percentage points, primarily due to high-margin self-operated products [2][18] - The non-GAAP net profit for FY2026H1 reached 260 million yuan, with a profit margin of 6.3% compared to 0.0% and 4.5% in FY2025H1 and H2 respectively, indicating continued improvement in profitability [2][18] High-Frequency Updates: Momentum Upward, Frequent Self-Operated Bestsellers - The company has over 800 self-operated products and plans to exceed 1,000 SKUs, entering a rapid iteration testing phase [4][19] - The company has successfully developed popular products such as probiotics and soft candies, with recent launches like dried apples and five-red powder also performing well [4][20] Accelerating Multi-Channel Strategy Implementation, Supporting Brand Momentum - The company is transitioning from a reliance on live-streaming sales to a focus on high-quality products, with significant sales through Douyin and its app [5][19] - The app sales GMV for FY2026H1 reached 760 million yuan, a year-on-year increase of 16% [5][19] New Development Phase Gradually Realized, Growth Accelerated in January 2026 - Estimated GMV for January 2026 exceeded 1 billion yuan, with a year-on-year growth rate exceeding 30%, driven by the launch of multiple new product lines and matrix accounts [6][19] Profit Forecast and Valuation - The company is expected to accelerate self-operated product and channel expansion, with adjusted net profit forecasts for FY2026-2028 at 556 million, 669 million, and 800 million yuan respectively, corresponding to PE ratios of 45x, 38x, and 31x [7][19]